Literature DB >> 15930203

Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.

Ronald T Brown, Robert W Amler, Wendy S Freeman, James M Perrin, Martin T Stein, Heidi M Feldman, Karen Pierce, Mark L Wolraich.   

Abstract

The American Academy of Pediatrics' Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder, reviewed and analyzed the current literature for the purpose of developing an evidence-based clinical practice guideline for the treatment of the school-aged child with attention-deficit/hyperactivity disorder (ADHD). This review included several key reports, including an evidence review from the McMaster Evidence-Based Practice Center (supported by the Agency for Healthcare Research and Quality), a report from the Canadian Coordinating Office for Health Technology Assessment, the Multimodal Treatment for ADHD comparative clinical trial (supported by the National Institute of Mental Health), and supplemental reviews conducted by the subcommittee. These reviews provided substantial information about different treatments for ADHD and their efficacy in improving certain characteristics or outcomes for children with ADHD as well as adverse effects and benefits of multiple modes of treatment compared with single modes (eg, medication or behavior therapies alone). The reviews also compared the effects of different medications. Other evidence documents the long-term nature of ADHD in children and its classification as a chronic condition, meriting the application of general concepts of chronic-condition management, including an individual treatment plan with a focus on ongoing parent and child education, management, and monitoring. The evidence strongly supports the use of stimulant medications for treating the core symptoms of children with ADHD and, to a lesser degree, for improving functioning. Behavior therapy alone has only limited effect on symptoms or functioning of children with ADHD, although combining behavior therapy with medication seems to improve functioning and may decrease the amount of (stimulant) medication needed. Comparison among stimulants (mainly methylphenidate and amphetamines) did not indicate that 1 class outperformed the other.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930203     DOI: 10.1542/peds.2004-2560

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  75 in total

1.  Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat.

Authors:  Michael H Baumann; Zakia Williams; Dorota Zolkowska; Richard B Rothman
Journal:  Drug Alcohol Depend       Date:  2010-11-10       Impact factor: 4.492

2.  The Role of Parental Knowledge and Attitudes about ADHD and Perceptions of Treatment Response in the Treatment Utilization of Families of Children with ADHD.

Authors:  Rosanna Breaux; Daniel A Waschbusch; Rebecca Marshall; Hugh Humphrey; William E Pelham; James G Waxmonsky
Journal:  Evid Based Pract Child Adolesc Ment Health       Date:  2020-03-24

3.  Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.

Authors:  Atilla Turgay; Lawrence Ginsberg; Elias Sarkis; Rakesh Jain; Ben Adeyi; Joseph Gao; Bryan Dirks; Thomas Babcock; Brian Scheckner; Cynthia Richards; Robert Lasser; Robert L Findling
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-12       Impact factor: 2.576

4.  Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Heather M Conklin; Susan Helton; Jason Ashford; Raymond K Mulhern; Wilburn E Reddick; Ronald Brown; Melanie Bonner; Bruce W Jasper; Shengjie Wu; Xiaoping Xiong; Raja B Khan
Journal:  J Pediatr Psychol       Date:  2009-05-22

5.  Food additives and hyperactivity.

Authors:  Andrew Kemp
Journal:  BMJ       Date:  2008-05-24

6.  Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials.

Authors:  Bjørn E Ramtvedt; Elisabeth Røinås; Henning S Aabech; Kjetil S Sundet
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-09       Impact factor: 2.576

Review 7.  Quantitative electroencephalography and attention-deficit/hyperactivity disorder: implications for clinical practice.

Authors:  Vincent J Monastra
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

8.  Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8-15 years: National Health and Nutrition Examination Survey 2001-2004.

Authors:  H C M Byrd; C Curtin; S E Anderson
Journal:  Pediatr Obes       Date:  2013-01-16       Impact factor: 4.000

9.  Growth effects of methylphenidate among childhood cancer survivors: a 12-month case-matched open-label study.

Authors:  Bruce W Jasper; Heather M Conklin; Joanne Lawford; E Brannon Morris; Scott C Howard; Shengjie Wu; Xiaoping Xiong; John Shelso; Raja B Khan
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

10.  The influence of task environment and health literacy on the quality of parent-reported ADHD data.

Authors:  S C Porter; C-Y Guo; J Molino; S L Toomey; E Chan
Journal:  Appl Clin Inform       Date:  2012-01-18       Impact factor: 2.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.